Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study
Tóm tắt
Menopausal hormone therapy has been reported to increase the risk of certain subtypes of breast cancer and to be associated with a favorable survival. These associations could either be due to an increased mammographic surveillance or to a biological effect. We assessed these associations in a Swedish cohort of postmenopausal breast cancer patients holding information on mammographic examinations, menopausal hormone therapy use, other breast cancer risk factors, and cancer treatment. We analyzed 2,660 postmenopausal women aged 50 to 74 years, diagnosed with invasive breast cancer in 1993 to 1995 and followed until the end of 2003 (median follow-up, 9 years and 3 months). We assessed the influence of hormone therapy before diagnosis on tumor characteristics and breast cancer-specific survival. We analyzed hormone therapy before diagnosis by regimen (estrogen–progestin therapy or estrogen alone therapy), recency (current or past), and duration of use (<5 years or ≥ 5 years). Current use, but not past use, compared with never use of hormone therapy before diagnosis seemed to be associated with tumors of low grade and with improved breast cancer-specific survival. The associations were stronger with longer duration, but did not vary significantly by regimen. The favorable survival among current users of hormone therapy was only partly explained by differences in available tumor characteristics and mammographic surveillance. We conclude that current menopausal hormone therapy, especially long term, is associated with favorable tumor characteristics and survival.
Tài liệu tham khảo
Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14596-5.
Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Jama. 2003, 289: 3243-3253. 10.1001/jama.289.24.3243.
Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ: Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. Bmj. 1996, 312: 1646-1647.
Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I: Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat. 1996, 38: 325-334. 10.1007/BF01806152.
Holli K, Isola J, Cuzick J: Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol. 1998, 16: 3115-3120.
Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Goldstein L: Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol. 1999, 17: 1680-1688.
Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN: Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999, 91: 264-270. 10.1093/jnci/91.3.264.
Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA, Hole D: Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. Bmj. 2000, 320: 348-349. 10.1136/bmj.320.7231.348.
Esteve J, Seradour B, Jacquemier J, Remontet L: Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography. J Med Screen. 2002, 9: 70-73. 10.1136/jms.9.2.70.
Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G, Veronesi U: Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol. 2002, 9: 266-271.
Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R: Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50–64 years. Cancer Epidemiol Biomarkers Prev. 2003, 12: 1175-1181.
Gertig DM, Erbas B, Fletcher A, Amos A, Kavanagh AM: Duration of hormone replacement therapy, breast tumour size and grade in a screening programme. Breast Cancer Res Treat. 2003, 80: 267-273. 10.1023/A:1024953926221.
Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA: Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003, 21: 4314-4321. 10.1200/JCO.2003.05.151.
Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Moller S, Rank F, Ottesen B, Lynge E: Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer. 2004, 91: 644-650.
Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99: 1335-1339. 10.1093/jnci/djm111.
Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen–progestogen replacement therapy. Am J Epidemiol. 1989, 130: 221-228.
Ewertz M, Gillanders S, Meyer L, Zedeler K: Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer. 1991, 49: 526-530. 10.1002/ijc.2910490409.
Strickland DM, Gambrell RD, Butzin CA, Strickland K: The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol. 1992, 80: 400-404.
Jernstrom H, Frenander J, Ferno M, Olsson H: Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer. 1999, 80: 1453-1458. 10.1038/sj.bjc.6690543.
Fletcher AS, Erbas B, Kavanagh AM, Hart S, Rodger A, Gertig DM: Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis. Breast. 2005, 14: 192-200. 10.1016/j.breast.2004.08.018.
Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I: Breast-cancer risk following long-term oestrogen- and oestrogen–progestin-replacement therapy. Int J Cancer. 1999, 81: 339-344. 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6.
Nystrom L, Larsson LG, Rutqvist LE, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L: Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol. 1995, 34: 145-152. 10.3109/02841869509093948.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.
Lacroix M, Toillon RA, Leclercq G: Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer. 2004, 11: 497-522. 10.1677/erc.1.00758.
Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol. 2005, 205: 248-254. 10.1002/path.1691.
Webster LR, Bilous AM, Willis L, Byth K, Burgemeister FC, Salisbury EL, Clarke CL, Balleine RL: Histopathologic indicators of breast cancer biology: insights from population mammographic screening. Br J Cancer. 2005, 92: 1366-1371. 10.1038/sj.bjc.6602501.
Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000, 92: 328-332. 10.1093/jnci/92.4.328.
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk. Jama. 2000, 283: 485-491. 10.1001/jama.283.4.485.
Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J: Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer. 2007, 120: 2202-2207. 10.1002/ijc.22542.
Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT: Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. Jama. 2006, 295: 1647-1657. 10.1001/jama.295.14.1647.
Bonnier P, Bessenay F, Sasco AJ, Beedassy B, Lejeune C, Romain S, Charpin C, Piana L, Martin PM: Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer. 1998, 79: 278-282. 10.1002/(SICI)1097-0215(199806)79:3<278::AID-IJC12>3.0.CO;2-5.
Anderson WF, Jatoi I, Devesa SS: Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat. 2005, 90: 127-137. 10.1007/s10549-004-3777-3.
Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99: 1152-1161. 10.1093/jnci/djm059.
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.
Apoteket. [http://www2.apoteket.se/Apoteket/om/VadViGor/Forsalj/Publicerad_statistik/default.htm]
Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S: Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod. 2007, 22: 616-622. 10.1093/humrep/del393.